Merck (MRK) completes takeover of Imago BioSciences Jan 11, 2023 06:46AM
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc. Jan 11, 2023 06:45AM
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis Dec 20, 2022 04:05PM
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022 Dec 12, 2022 11:30AM
Imago BioSciences (IMGO) Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022 Dec 12, 2022 10:05AM


Dec 12, 2022 10:00AM Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
Dec 12, 2022 06:45AM Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Nov 30, 2022 04:05PM Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
Nov 21, 2022 09:30AM Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall
Nov 21, 2022 06:46AM Merck (MRK) Acquires Imago BioSciences (IMGO) for $36/sh or $1.35B
Nov 21, 2022 06:45AM Merck to Acquire Imago BioSciences, Inc.
Nov 9, 2022 04:05PM Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
Nov 7, 2022 04:05PM Imago BioSciences to Participate in Upcoming Investor Conferences
Nov 3, 2022 09:00AM Imago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
Sep 6, 2022 04:05PM Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 12, 2022 04:05PM Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Aug 3, 2022 04:57PM Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Jun 10, 2022 05:36AM ​Imago BioSciences (IMGO) Reports Positive Data from Ongoing Phase 2 Study of Bomedemstat
Jun 10, 2022 03:00AM Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
Jun 10, 2022 03:00AM Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
Jun 6, 2022 05:24PM Imago BioSciences to Host Virtual Investor Event
May 16, 2022 08:00AM Imago BioSciences to Participate in Upcoming Investor Conferences
May 12, 2022 04:05PM Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
May 12, 2022 08:00AM Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the Euro
May 9, 2022 08:00AM Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
May 3, 2022 08:00AM Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
Mar 24, 2022 04:05PM Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 23, 2022 04:06PM ​Imago BioSciences (IMGO) Appoints Michael Arenberg as COO and CBO
Mar 23, 2022 04:05PM Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer
Feb 28, 2022 04:05PM Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
Feb 4, 2022 04:05PM Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
Jan 19, 2022 08:00AM PepGen Appoints Laurie Keating as Chair of Board of Directors
Dec 13, 2021 05:23AM ​Imago BioSciences (IMGO) Reports Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis
Dec 13, 2021 05:02AM ​Imago BioSciences (IMGO) Reports Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia
Dec 12, 2021 09:46AM Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
Dec 11, 2021 12:01PM Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
Nov 10, 2021 04:05PM Imago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business Updates
Aug 19, 2021 04:01PM Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates